Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry

ConclusionsAmong real-world patients with psoriasis who achieved PASI90 with biologic therapy, about one-quarter lost response at 6  months, and half lost response at 18 months. Prior use of a biologic therapy and clinically meaningful skin symptoms at index, including itch and skin pain, were associated with loss of treatment response. Therefore, dermatologists may consider focusing on patient-reported symptoms as part of any intervention designed to reduce the likelihood of loss of response to biologic therapies.Trial RegistrationClinicalTrials.gov identifier, NCT02707341.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research